We propose that the functional and molecular changes in PTEN and CK2 we uncovered could be used to increase the precision of early GBM patient stratification, and in the development of combinatorial therapies directed towards combating therapeutic resistance in GBMs with aberrancies in p53, PTEN and CK2. The gene discussed is PTEN; the disease is glioblastoma.